# US 2023/0271986 A1 · Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0271986 A1
- Document ID: US20230271986A1
- Status: Published application
- Kind: A1
- Application number: 18/015,883
- Filed: 2021-07-12
- Published: 2023-08-31
- Earliest claimed: 2020-07-13
- Assignees: Ascentage Pharma (Suzhou) Co., Ltd.; Ascentage Pharma Group Corp Limited
- Applicants: Ascentage Pharma (Suzhou) Co., Ltd.; Ascentage Pharma Group Corp Limited
- Inventors: Jianfeng WEN; Yanqiong LIN; Jianpeng FENG; Zhenzhong SHAO; Huirong LU; Weidong LI
- Web page: https://patentgrep.com/patent/US20230271986A1

## CPC

- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07C 51/41: Preparation of salts of carboxylic acids ({C07C51/093 - C07C51/34 take precedence} preparation of soap C11D)
- C07C 55/14: Adipic acid
- C07C 57/145: Maleic acid
- C07C 57/15: Fumaric acid
- C07C 215/10: with one amino group and at least two hydroxy groups bound to the carbon skeleton
- C07D 213/80: in position 3
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed herein are a crystalline or amorphous form of a Bcl-2/Bcl-xL inhibitor compound or a salt thereof, and a preparation method and application thereof.

## Claims

### Claim 1

A crystalline or amorphous form of the compound of formula 1 or its salt:

### Claim 2 (depends on 1)

The form of claim 1, wherein the form is the crystalline form I of the fumarate salt of the compound of formula 1;
the crystalline form II of the hydrochloride salt of the compound of formula 1;
the nicotinate crystalline form III of the compound of formula 1;
the sodium salt crystalline form IV of the compound of formula 1;
the crystalline form V of the potassium salt of the compound of formula 1;
the crystalline form VI of the compound of formula 1;
the crystalline form VII of the compound of formula 1;
the crystalline form VIII of the compound of formula 1;
the adipate salt amorphous form IX of the compound of formula 1;
the fumarate amorphous form X of the compound of formula 1;
the nicotinic acid salt amorphous form XI of the compound of formula 1;
the amorphous form XII of the potassium salt of the compound of formula 1;
the amorphous form XIII of the sodium salt of the compound of formula 1;
the amorphous form XIV of the compound of formula 1;
the amorphous form XV of the maleate salt of the compound of formula 1; or
the amorphous form XVI of the meglumine salt of the compound of formula 1.

### Claim 3 (depends on 2)

The form of claim 2, wherein the form is the crystalline form I of the fumarate salt of the compound of formula 1, characterized in that it has characteristic peaks at the following positions in an X-ray powder diffraction (XRPD) pattern represented by an angle of 2θ: 18.03±0.2°, 28.81±0.2° and 31.88±0.2°, and wherein the form has one or more of the following:
1) XRPD characteristic peaks at positions substantially similar to Table 1;
2) an XRPD pattern substantially similar to FIG. 1;
3) an endothermic peak at 217.4±2.0° C. measured from modulated differential scanning calorimetry (MDSC); and
4) MDSC endothermic peaks substantially similar to FIG. 2.

### Claim 4 (depends on 2)

The form of claim 2, wherein the form is the crystalline form II of the hydrochloride salt of the compound of formula 1, characterized in that it has characteristic peaks at the following positions in the XRPD diagram represented by an angle of 2θ: 13.01±0.2°, 21.55±0.2°, 25.95±0.2°, 31.33±0.2° and 37.34±0.2, and wherein the form has one or more of the following:
1) XRPD characteristic peaks at positions substantially similar to Table 2;
2) an XRPD pattern substantially similar to FIG. 3;
3) an endothermic peak at 148.2±2.0° C. and a glass transition temperature at 139.5±2.0° C. measured from MDSC; and
4) MDSC endothermic peaks substantially similar to FIG. 4.

### Claim 5

(canceled)

### Claim 6 (depends on 2)

The form of claim 2, wherein the form is the nicotinate crystalline form III of the compound of formula 1, characterized in that it has characteristic peaks at the following positions in the XRPD diagram expressed at 2θ angles: 15.46±0.2° and 18.06±0.2°, and wherein the form has one or more of the following:
1) XRPD characteristic peaks at positions substantially similar to Table 3;
2) an XRPD pattern substantially similar to FIG. 5;
3) a glass transition temperature at 127.6±2.0° C. measured by MSDC; and
4) MDSC endothermic peaks substantially similar to FIG. 6.

### Claim 7

(canceled)

### Claim 8 (depends on 2)

The form of claim 2, wherein the form is the sodium salt crystalline form IV of the compound of formula 1, characterized in that it has characteristic peaks at the following positions in the XRPD diagram expressed at 2θ angles: 16.75±0.2°, 32.34±0.2°, 33.48±0.2° and 37.95±0.2°, and wherein the form has one or more of the following:
1) XRPD characteristic peaks at positions substantially similar to Table 4; and
2) an XRPD pattern substantially similar to FIG. 7.

### Claim 9

(canceled)

### Claim 10 (depends on 2)

The form of claim 2, wherein the form is the crystalline form V of the potassium salt of the compound of formula 1, characterized in that it has characteristic peaks at the following positions in the XRPD diagram represented by an angle of 2θ: 24.35±0.2°, 30.10±0.2° and 31.41±0.2°, and wherein the form has one or more of the following:
1) XRPD characteristic peaks at positions substantially similar to Table 5; and
2) an XRPD pattern substantially similar to FIG. 8.

### Claim 11

(canceled)

### Claim 12 (depends on 2)

The form of claim 2, wherein the form is the crystalline form VI of the compound of formula 1, characterized in that it has characteristic peaks at the following positions in the XRPD diagram represented by an angle of 2θ: 3.94±0.2°, 5.09±0.2°, 18.01±0.2°, 19.08±0.2°, 19.70±0.2°, and wherein the form has one or more of the following:
1) XRPD characteristic peaks at positions substantially similar to Table 6;
2) an XRPD pattern substantially similar to FIG. 9;
3) a weight loss of 7.01±0.2% by weight before 160° C. measured by Thermogravimetric Analysis (TGA);
4) endothermic peaks at the peak temperature of 78.8±2.0° C. and −162.5±2.0° C. measured by differential scanning calorimetry (DSC);
5) a TGA diagram substantially similar to FIG. 10; and
6) a DSC chart substantially similar to FIG. 11.

### Claim 13

(canceled)

### Claim 14 (depends on 2)

The form of claim 2, wherein the form is the crystalline form VII of the compound of formula 1, characterized in that it has characteristic peaks at the following positions in the XRPD diagram represented by 2θ angles: 20.18±0.2°, 20.74±0.2°, 29.20±0.2°, 29.28±0.2° and 36.73±0.2°, and wherein the form has one or more of the following:
1) XRPD characteristic peaks at positions substantially similar to Table 7;
2) an XRPD pattern substantially similar to FIG. 12;
3) endothermic peaks at peak temperatures of 77.5±2.0° C. and 195.7±2.0° C. measured by DSC; and
4) a DSC chart substantially similar to FIG. 13.

### Claim 15

(canceled)

### Claim 16 (depends on 2)

The form of claim 2, wherein the form is the crystalline form VIII of the compound of formula 1, characterized in that it has a characteristic peak at the following position in the XRPD diagram represented by an angle of 2θ: 18.11±0.2°, and wherein the form has one of the following:
1) XRPD characteristic peaks at positions substantially similar to Table 8;
2) an XRPD pattern substantially similar to FIG. 14;
3) a weight loss of 7.59±0.2% by weight before 150° C. measured by TGA;
4) endothermic peaks at peak temperatures of 69.3±2.0° C. and 152.1±2.0° C. measured by DSC;
5) a TGA diagram substantially similar to FIG. 15; and
6) a DSC chart substantially similar to FIG. 16.

### Claim 17

(canceled)

### Claim 18 (depends on 2)

The form of claim 2, wherein the form is selected from the group consisting of:
the adipate salt amorphous form IX of the compound of formula 1, wherein the form has one or more of the following:
1) an XRPD pattern substantially similar to FIG. 17;
2) a glass transition temperature at 113.4±2.0° C. measured by MDSC; and
3) an MDSC chart substantially similar to FIG. 18;
the fumarate amorphous form X of the compound of formula 1, wherein the form has one or more of the following:
1) an XRPD pattern substantially similar to FIG. 19;
2) a glass transition temperature at 136.6±2.0° C. measured by MDSC; and
3) an MDSC chart substantially similar to FIG. 20;
the nicotinic acid salt amorphous form XI of the compound of formula 1, wherein the form has one or more of the following:
1) an XRPD pattern substantially similar to FIG. 21;
2) a glass transition temperature at 117.9±2.0° C. measured by MDSC; and
3) an MDSC chart substantially similar to FIG. 22;
the amorphous form XII of the potassium salt of the compound of formula 1, wherein the form has one or more of the following:
1) an XRPD pattern substantially similar to FIG. 23;
2) a glass transition temperature at 135.7±2.0° C. measured by MDSC; and
3) an MDSC chart substantially similar to FIG. 24;
the amorphous form XIII of the sodium salt of the compound of formula 1, wherein the form has one or more of the following:
1) an XRPD pattern substantially similar to FIG. 25;
2) a glass transition temperature at 140.9±2.0° C. measured by MDSC; and
3) an MDSC chart substantially similar to FIG. 26;
the amorphous form XIV of the compound of formula 1, wherein the form has one or more of the following:
1) an XRPD pattern substantially similar to FIG. 27;
2) a glass transition temperature at 148.9±2.0° C. measured by MDSC;
3) a weight loss of 6.35±0.2% by weight before 200° C. measured by TGA;
4) an MDSC chart substantially similar to FIG. 28; and
4) a TGA diagram substantially similar to FIG. 29;
the amorphous form XV of the maleate salt of the compound of formula 1, wherein the form has one or more of the following:
1) an XRPD pattern substantially similar to FIG. 30;
2) a glass transition temperature at 91.89±2.0° C. measured by MDSC;
3) a weight loss of 8.767±0.2% by weight before 223.63° C. measured by TGA;
4) an MDSC chart substantially similar to FIG. 31; and
5) a TGA diagram substantially similar to FIG. 32;
and the amorphous form XVI of the meglumine salt of the compound of formula 1, wherein the form has one or more of the following:
1) an XRPD pattern substantially similar to FIG. 33;
2) a glass transition temperature at 66.19±2.0 measured by MDSC;
3) a weight loss of 2.416±0.2% by weight before 124.19° C. and a weight loss of 2.774±0.2% by weight between 187.71° C. and 124.19° C. measured by TGA;
4) an MDSC chart substantially similar to FIG. 34; and
5) a TGA diagram substantially similar to FIG. 35.

### Claim at position 19

19-25. (canceled)

### Claim 26 (depends on 2)

The method for preparing any one of the crystalline forms I-V of the salt of the compound of formula 1 according to claim 2, comprising:
mixing the compound of formula 1 with a solvent and an acid or a base, and with volatilization at room temperature;
wherein the solvent is selected from one or more of: water, alkane, alcohol, ketone, ester, aromatic hydrocarbon, halogenated hydrocarbon, nitrile, ether, aliphatic hydrocarbons solvents and polar aprotic solvents such as DMF and DMSO;
wherein the mass-volume ratio of the compound of formula 1 to the solvent is 100 mg:(0.1-10 mL);
wherein the acid is fumaric acid, hydrochloric acid, niacin, or maleic acid; and
wherein the base is sodium hydroxide, potassium hydroxide, or meglumine.

### Claim 27

(canceled)

### Claim 28 (depends on 2)

The method according to claim 2, further comprising: dissolving the compound of formula 1 in ethyl acetate, adding L-malic acid, and separating the obtained solid to obtain the crystalline form VII of the compound of formula 1.

### Claim 29 (depends on 2)

The method according to claim 2, further comprising: dissolving the compound of formula 1 in acetone, adding methanol, and separating the obtained solid to obtain the crystalline form VI of the compound of formula 1.

### Claim 30 (depends on 2)

The method according to claim 2, further comprising: adding the compound of formula 1 to a tetrahydrofuran/n-hexane mixed solvent and separating the obtained solid to obtain the crystalline form VIII of the compound of formula 1.

### Claim 31 (depends on 18)

The method for preparing any one of the amorphous forms IX-XIII and XV-XVI of the salt of the compound of formula 1 according to claim 18, wherein the method comprises:
mixing the compound of formula 1 with a solvent and an acid or base, and separating the resulting solid to obtain the compound of formula 1 amorphous form of salt;
wherein the solvent is selected from one or more of water, alkane, alcohol, ketone, ester, aromatic hydrocarbon, halogenated hydrocarbon, nitrile, ether, aliphatic hydrocarbons solvents, polar aprotic solvents such as DMF and DMSO;
wherein the mass-volume ratio of the compound of formula 1 to the solvent is 100 mg:(0.1-10 mL);
wherein the acid is fumaric acid, hydrochloric acid, niacin, or maleic acid; and
wherein the base is sodium hydroxide, potassium hydroxide, or meglumine.

### Claim 32

(canceled)

### Claim 33 (depends on 18)

The method for preparing the amorphous form XIV of the compound of formula 1 according to claim 18, wherein the method comprises:
adding the compound of formula 1 to a solvent to obtain a solution, adding the obtained solution to an anti-solvent, and separating the obtained solid to obtain the amorphous form XIV of compound of formula 1;
wherein the solvent is selected from one or more of ethyl acetate, acetone, tetrahydrofuran, acetonitrile, DMSO, 1,4-dioxane, MIBK, dichloromethane, and DMF; and
wherein the anti-solvent is selected from one or more of heptane, ethanol, water, IPAc, IPA, butanol, and NPA.

### Claim 34 (depends on 1)

A pharmaceutical composition comprising the crystalline or amorphous form of the compound of Formula 1 or its salt according to claim 1, and pharmaceutically acceptable excipients.

### Claim 35 (depends on 1)

A method of treating a Bcl-2 or Bcl-xL disease, comprising administering the crystalline form or amorphous form of the compound of formula 1 or its salt according to claim 1 to a patient in need thereof.

### Claim 36 (depends on 35)

The method of claim 35, wherein the Bcl-2 or Bcl-xL disease is selected from the group consisting of bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, testicular cancer, genitourinary tract cancer, lymphatic system cancer, rectal cancer, Laryngeal cancer, pancreatic cancer, esophageal cancer, gastric cancer, gallbladder cancer, cervical cancer, thyroid cancer, skin cancer, hematopoietic tumors of the lymphatic system, including leukemia, acute lymphoblastic leukemia, acute lymphoblastic leukemia, B-cell lymph Tumor, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hair cell lymphoma, histiocytic lymphoma and Burketts lymphoma; hematopoietic tumors of the bone marrow line, including acute and chronic myelogenous leukemia, bone marrow Dysplasia syndrome, myelogenous leukemia and promyelocytic leukemia; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannoma; tumors of mesenchymal origin, Including fibrosarcoma, rhabdomyosarcoma and osteosarcoma; and other tumors, including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular carcinoma, teratoma, renal cell carcinoma (RCC), Myeloma, myelogenous and lymphoblastic leukemia, neuroblastoma and glioblastoma.
